The three-year signature initiative is designed to make learning about health and disease engaging, accessible, and exciting for students in grades 6-8, primarily in under-resourced schools across the country.
The programme will kick off with a Virtual Field Trip to AstraZeneca's Gaithersburg, MD, research laboratories, which will premiere on Tuesday, October 8, 2019 at 1:00 p.m. ET / 10:00 a.m. PT.
The programme, Generation Health: How Science Powers Us, will provide students first-hand access to the technology and scientists working to create medical breakthroughs for the world's most pressing health problems. Educators, parents and students are invited to register here.
Participants are encouraged to join a live Twitter chat during the premiere by submitting questions and sending pictures using #GenerationHealthVFT.
Generation Health: How Science Powers Us will provide hands-on, standards-aligned STEM learning activities where students investigate both preventative measures and innovative solutions to key health concerns in the areas of oncology, cardiovascular, and respiratory disease.
The programme will also offer resources for employee engagement in the classroom.
As part of this program, Generation Health provides a suite of educational resources, including, Learning Undefeated's Drop Anywhere Labs, custom-outfitted STEM learning spaces built from modified shipping containers.
These light, easy-to-access and inexpensive labs provide a range of career and skills education for middle school students, as well as flexible in-classroom resources that empower teachers and enables them to serve up to four classes simultaneously.
Hemogenyx Pharmaceuticals advances HG-CT-1 trial and opens paediatric recruitment
Rx to Go receives ACHC re-accreditation for pharmacy services
Shanton Pharma completes SAP-001 End-of-Phase 2 meeting with US FDA
Fibronostics completes Stone Clinical Laboratories acquisition
Syngene International to add GMP bioconjugation suite in Bengaluru
Eli Lilly's single-injection, once-monthly maintenance Omvoh regimen receives US FDA approval
4basebio synthetic DNA used in Phase I/II mRNA therapy trial